Arcus Biosciences Inc.
RCUS
We are a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our inflammation and autoimmune disease progr…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$100M
▼ -4.3% YoY
Net Income (TTM)
-$453M
▼ -24.7% YoY
Op. Margin
-475.00%
▼ -28.4pp YoY
ROIC
-59.61%
▲ +1.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$466M
▼ -175.0% YoY
Op. Cash Flow (TTM)
-$465M
▼ -183.5% YoY
Net Debt
-$514M
Net Cash Position
Cash & Equiv.
$630M
5Y CAGR: +25.9%
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with RCUS
Held by ETFs
RCUS is in 65 US ETFs. The largest of them, with RCUS's weight in each:
Arcus Biosciences (RCUS) in four numbers
Questions about Arcus Biosciences
Is Arcus Biosciences (RCUS) overvalued?
At $18.95, Arcus Biosciences' price is 206% above the $6.20 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Arcus Biosciences' fair value?
Intrinsiqq's calculator puts Arcus Biosciences' fair value at $6.20 a share. It grows revenue per share 13.9% a year for 5 years, applies an exit P/S of 7.5, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $4.65. Every input can be changed on the Intrinsic Value tab.
Is Arcus Biosciences a high-quality business?
Arcus Biosciences scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is net debt at -$514M, and its weakest is return on capital at -59.6%. The Quality tab shows every check against its target.
Does Arcus Biosciences (RCUS) pay a dividend?
No. Arcus Biosciences (RCUS) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 29 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 9 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in RCUS's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing RCUS
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.